Sernova Corp. (CVE:SVA) Expected to Post FY2022 Earnings of ($0.07) Per Share

Sernova Corp. (CVE:SVAGet Rating) – Equities researchers at Echelon Wealth Partners decreased their FY2022 earnings per share (EPS) estimates for Sernova in a report released on Tuesday, May 17th. Echelon Wealth Partners analyst S. Quenneville now anticipates that the company will earn ($0.07) per share for the year, down from their previous estimate of ($0.06). Echelon Wealth Partners currently has a “Speculative Buy” rating on the stock. Echelon Wealth Partners also issued estimates for Sernova’s FY2023 earnings at ($0.09) EPS and FY2024 earnings at ($0.10) EPS.

Shares of SVA opened at C$1.46 on Friday. Sernova has a 1 year low of C$1.16 and a 1 year high of C$2.22. The company has a debt-to-equity ratio of 1.34, a current ratio of 13.76 and a quick ratio of 13.59. The company has a market capitalization of C$383.37 million and a price-to-earnings ratio of -34.76. The business has a 50-day moving average of C$1.45 and a 200-day moving average of C$1.49.

Sernova (CVE:SVAGet Rating) last issued its quarterly earnings data on Tuesday, March 29th. The company reported C($0.02) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of C($0.01) by C($0.01).

About Sernova (Get Rating)

Sernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection.

Recommended Stories

Receive News & Ratings for Sernova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sernova and related companies with's FREE daily email newsletter.